Investigation of the effect of planning techniques on thyroid and lens absorbe doses in radiotherapy of left breast cancer by in vivo dosimetry: a prospective study
Physical and Engineering Sciences in Medicine · 2026-06 · 49 (2) · 1077-1085
DOI: 10.1007/s13246-026-01722-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physical and Engineering Sciences in Medicine, online erschienen am 12.03.2026. Verfasst von Osman Vefa Gul und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Faculty of Medicine, Selcuk University, Konya, Turkey. vefagul@selcuk.edu.tr. Die Arbeit nennt 44 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Faculty of Medicine, Selcuk University, Konya, Turkey. vefagul@selcuk.edu.tr.
- Department of Radiation Oncology, Faculty of Medicine, Selcuk University, Konya, Turkey.
Zitieren
APA
Gul, O. V., Basaran, H., Duzova, M., & Yavas, C. (2026). Investigation of the effect of planning techniques on thyroid and lens absorbe doses in radiotherapy of left breast cancer by in vivo dosimetry: a prospective study. Physical and Engineering Sciences in Medicine, 49(2), 1077-1085. https://doi.org/10.1007/s13246-026-01722-6
Vancouver
Gul OV, Basaran H, Duzova M, Yavas C. Investigation of the effect of planning techniques on thyroid and lens absorbe doses in radiotherapy of left breast cancer by in vivo dosimetry: a prospective study. Physical and Engineering Sciences in Medicine. 2026;49(2):1077-1085. doi:10.1007/s13246-026-01722-6
BibTeX
@article{Gul2026,
author = {Gul, Osman Vefa and Basaran, Hamit and Duzova, Mursel and Yavas, Cagdas},
title = {Investigation of the effect of planning techniques on thyroid and lens absorbe doses in radiotherapy of left breast cancer by in vivo dosimetry: a prospective study},
journal = {Physical and Engineering Sciences in Medicine},
year = {2026},
volume = {49},
number = {2},
pages = {1077--1085},
doi = {10.1007/s13246-026-01722-6}
}
EUVIMED